Drugs / Vicadrostat
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT07513207 | Apr → Jul 2026 overdue | — | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07133399 | Sep → Oct 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07035457 | Jul → Aug 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06647810 | Nov → Dec 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05731908 | Feb → Apr 2023 | liver disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05515588 | Sep → Nov 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03608072 | Aug 2018 → Jan 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03165240 | Oct 2017 → Apr 2020 | diabetic kidney disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03206632 | Jul → Oct 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03100916 | May → Nov 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02891148 | Sep → Dec 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07304817 | May 2026 → Feb 2028 expected | chronic kidney disease, heart failure | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 2 | NCT06926660 | Jul 2025 → Aug 2026 overdue | chronic kidney disease | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05182840 | Jan 2022 → Jun 2023 | chronic kidney disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07064473 | Jul 2025 → Dec 2029 expected | hypertensive disorder, type 2 diabetes mellitus | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT06935370 | May 2025 → Feb 2029 expected | heart failure | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT06531824 | Aug 2024 → Aug 2028 expected | chronic kidney disease | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT06424288 | Jun 2024 → May 2028 expected | heart failure | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vicadrostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07133399 ↗ |
| Known as | BI 690517 | “vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure.” NCT06424288 ↗ |
| Action | Inhibit | “Aldosterone synthase inhibitor (BI 690517)” PMID 38497241 ↗ Mar 2024 |
| Modality | Small molecule | — CHEMBL6068035 ↗ |
| Route | Oral | “once-daily oral BI 690517 3, 10 or 40 mg” PMID 38497241 ↗ Mar 2024 |